Programmed death ligand‐1 expression as immunotherapeutic target in sinonasal cancer

Abstract

The PD-L1 positivity does not seem to have prognostic value. However, a proportion of patients with sinonasal SCC and ITAC may benefit from therapy with immune checkpoint inhibitors that recently have been approved for clinical application in head and neck cancer.